Copley Acquisition Corp: terminates business combination agreement

What happened Copley Acquisition Corp filed an 8-K reporting that on Oct 9, 2026 the parties entered into a Mutual Termination of Business Combination Agreement, pursuant to which Copley and Ignite Proteomics, LLC mutually agreed to terminate the Business Combination Agreement dated Jun 10, 2026, effective immediately. The filing states that, as a result, no party has any further rights, remedies, liabilities or obligations under the Business Combination Agreement except for certain surviving provisions.

Key details

• The original Business Combination Agreement was entered on Jun 10, 2026 among Copley, Ignite Proteomics, LLC, Ignite Proteomics Holdings, Inc., two merger subsidiaries and certain representatives.
• The Termination Agreement was entered on Oct 9, 2026 and provides that Sections 6.14, 6.15, 8.2 and 9.1 and Article X of the Business Combination Agreement survive.
• Each Ancillary Document, including the Seller Support Agreements, the Insider Letter Amendment and the Lock-Up Agreements, automatically terminated concurrently with the Business Combination Agreement.
• The Termination Agreement provides that each party will bear its own expenses and contains mutual releases of claims relating to the Business Combination Agreement, other than claims under the Termination Agreement. Copley states it intends to continue to pursue a business combination and currently has until Nov 2, 2026 to consummate a business combination, subject to extension in accordance with its organizational documents.

Why it may matter This filing reports Item 1.02 (termination of a material definitive agreement) and references the earlier Item 1.01 disclosure of the Business Combination Agreement dated Jun 10, 2026; Item 1.02 covers the termination terms, surviving provisions and related releases and expense allocation. This filing contains forward-looking statements and notes related risks as set forth in Copley’s SEC filings. This filing does not show why the insider traded or why the company acted.